ReviewKidney international reports2020
Polycystins, ADPKD, and Cardiovascular Disease.
Review in Kidney international reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 63 citations in OpenAlex.
- Polycystin-1 suppresses apoptotic signalling in endothelial cells and protects from atherosclerosis.Cardiovascular research · 2026Article
- Polycystin-1 and Cardiac Remodeling: From Mechanotransduction to Clinical Consequences.Circulation research · 2026Review
- Role of Mediterranean Diet Adherence on Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease Patients.Biomolecules · 2026Article
- In vivo base editing rescues ADPKD in a humanized mouse model.Nature communications · 2025Article
- Physiological functions and pharmacological targeting of transient receptor potential channels.Pharmacological reviews · 2025Review
- Cardiac complications in autosomal dominant polycystic kidney disease: links to genotype and CKD severity.Clinical kidney journal · 2025Article
- Cardiovascular Complications in ADPKD.Kidney international reports · 2025Review
- RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management.Journal of cardiovascular translational research · 2025Review
- Autosomal Dominant Polycystic Kidney Disease: From Pathogenesis to Organoid Disease Models.Biomedicines · 2025Review
- Metformin Use and Clinical Outcomes in Autosomal Dominant Polycystic Kidney Disease: A Nationwide Cohort Study.Biomedicines · 2025Article
- Cardiac Localized Polycystin-2 in the Natriuretic Peptide Signaling Pathway and Hypertension.Journal of the American Society of Nephrology : JASN · 2025Article
- Echocardiographic characteristics of autosomal dominant polycystic kidney disease.Scientific reports · 2024Article
- Spontaneous Coronary Artery Dissection in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review of the Literature.Journal of personalized medicine · 2024Review
- Utilization of the genetically encoded calcium indicator Salsa6F in cardiac applications.Cell calcium · 2024Article
- Long-term health outcomes associated with hydration status.Nature reviews. Nephrology · 2024Review
- Cardiovascular perspectives of the TRP channel polycystin 2.The Journal of physiology · 2024Article
- Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement.International journal of molecular sciences · 2024Review
- TheBiomedicines · 2024Review
- Utilization of the genetically encoded calcium indicator Salsa6F in cardiac applications.bioRxiv : the preprint server for biology · 2023Article
- Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort study.BMC nephrology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disorders are the most common cause of mortality in autosomal dominant polycystic kidney disease (ADPKD). This review considers recent clinical and basic science studies that address the contributing factors of cardiovascular dysfunction in ADPKD. In particular, attention is placed on how dysfunction of the polycystin proteins located in the cardiovascular system contributes to extrarenal manifestations of ADPKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.